{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:40:34Z","timestamp":1793644834667,"version":"4.5.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,7,15]],"date-time":"2018-07-15T10:30:21Z","timestamp":1531650621000},"page":"5037-5045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States"],"prefix":"10.1016","volume":"36","author":[{"given":"D.","family":"Curran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Van Oorschot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Carrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Yawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6 Suppl 2","key":"10.1016\/j.vaccine.2018.07.005_b0005","first-page":"S13","article-title":"Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence","volume":"109","author":"Oxman","year":"2009","journal-title":"J Am Osteopath Assoc"},{"issue":"13","key":"10.1016\/j.vaccine.2018.07.005_b0010","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1056\/NEJMct066061","article-title":"Varicella-zoster vaccine for the prevention of herpes zoster","volume":"356","author":"Kimberlin","year":"2007","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.vaccine.2018.07.005_b0015","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.vaccine.2014.01.058","article-title":"Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review","volume":"32","author":"Kawai","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.005_b0020","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ncl.2008.03.011","article-title":"Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency","volume":"26","author":"Mueller","year":"2008","journal-title":"Neurol Clin"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.07.005_b0025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"issue":"11","key":"10.1016\/j.vaccine.2018.07.005_b0030","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.vaccine.2018.07.005_b0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jpain.2005.01.359","article-title":"Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey","volume":"6","author":"Oster","year":"2005","journal-title":"J Pain"},{"issue":"16","key":"10.1016\/j.vaccine.2018.07.005_b0040","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1503\/cmaj.091711","article-title":"The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study","volume":"182","author":"Drolet","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2018.07.005_b0045","unstructured":"Centers for Disease Control and Prevention (CDC). Shingles (herpes zoster): overview; 2016. Available from http:\/\/www.cdc.gov\/shingles\/about\/overview.html [accessed 2017 24 August]."},{"issue":"4","key":"10.1016\/j.vaccine.2018.07.005_b0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","article-title":"Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013","volume":"36","author":"McLaughlin","year":"2015","journal-title":"J Prim Prev"},{"issue":"1","key":"10.1016\/j.vaccine.2018.07.005_b0055","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12877-017-0420-9","article-title":"The temporal impact of aging on the burden of herpes zoster","volume":"17","author":"Varghese","year":"2017","journal-title":"BMC Geriatr"},{"issue":"05","key":"10.1016\/j.vaccine.2018.07.005_b0060","first-page":"1","article-title":"Advisory Committee on ImmunizationPractices, Centers for Disease Control and Prevention, Prevention of herpeszoster","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"33","key":"10.1016\/j.vaccine.2018.07.005_b0065","first-page":"729","article-title":"Update on recommendationsfor use of herpes zoster vaccine","volume":"63","author":"Hales","year":"2014","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.07.005_b0070","unstructured":"Merck. Zostavax prescribing information; 2016."},{"issue":"22","key":"10.1016\/j.vaccine.2018.07.005_b0075","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2018.07.005_b0080","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2018.07.005_b0085","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.07.005_b0090","unstructured":"GSK. Shingrix US prescribing information. Available from: https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm581605.pdf [accessed 2018 24 May]."},{"issue":"3","key":"10.1016\/j.vaccine.2018.07.005_b0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2018.07.005_b0100","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","article-title":"Assessment of the potential public health impact of Herpes Zoster vaccination in Germany","volume":"13","author":"Curran","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.07.005_b0105","unstructured":"Bureau USC. Annual estimates of the resident population by single year of age and sex for the United States: April 1, 2010 to July 1, 2015. Available from: https:\/\/factfinder.census.gov\/faces\/nav\/jsf\/pages\/community_facts.xhtml [accessed 2017 24 August]."},{"key":"10.1016\/j.vaccine.2018.07.005_b0110","unstructured":"Arias E, Heron M, Xu J.Q. United States life tables, 2012. National vital statistics reports. National Center for Health Statistics; 2016. Available from: https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr65\/nvsr65_08.pdf [accessed 2018 15 May]."},{"issue":"22","key":"10.1016\/j.vaccine.2018.07.005_b0115","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2018.07.005_b0120","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.07.005_b0125","unstructured":"Patterson BJ, Cheng WY, Trofa AF, Duchesneau A, Macheca M, Masseria C, Duh MS. A claims-based analysis of hepatitis a, b, and a\/b vaccination series completion and compliance among us adults. In: ISPOR 22nd annual international meeting; 2017."},{"key":"10.1016\/j.vaccine.2018.07.005_b0130","unstructured":"Centers for Disease Control and Prevention. CDC vaccines price list; 2017. Available from https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/ [accessed 2017 24 August]."},{"key":"10.1016\/j.vaccine.2018.07.005_b0135","series-title":"Decision and cost-effectiveness analyses of herpes zoster vaccination in adults 50 years of age and older [Presentation]","author":"Ortega-Sanchez","year":"2013"},{"key":"10.1016\/j.vaccine.2018.07.005_b0140","series-title":"Population norms for the EQ-5D","author":"Szende","year":"2014"},{"issue":"49","key":"10.1016\/j.vaccine.2018.07.005_b0145","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.07.005_b0150","unstructured":"Le P, Rothberg MB. How much is it worth to prevent shingles? Using cost-effectiveness analysis to determine value-based pricing of a new herpes zoster vaccine. In: 38th annual North American meeting of the society for medical decision making. Available from: https:\/\/smdm.confex.com\/smdm\/2016bc\/webprogram\/Paper10195.html [accessed 2017 24 August]."},{"issue":"10","key":"10.1016\/j.vaccine.2018.07.005_b0155","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1086\/514342","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"44","author":"Rothberg","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2018.07.005_b0160","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M15-0093","article-title":"Cost-effectiveness of herpes zoster vaccine for persons aged 50 years","volume":"163","author":"Le","year":"2015","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.005_b0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11606-016-3844-6","article-title":"Determining the optimal vaccination schedule for herpes zoster: a cost-effectiveness analysis","volume":"32","author":"Le","year":"2017","journal-title":"J Gen Intern Med"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.005_b0170","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","article-title":"Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults","volume":"178","author":"Le","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.005_b0175","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamainternmed.2017.7442","article-title":"Evolution of herpes zoster vaccines and their economic value","volume":"178","author":"Najafzadeh","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2018.07.005_b0180","article-title":"Persistence of immune response to an adjuvanted varicella\u2010zoster virus subunit candidate vaccine for up to year 9 in older adults","author":"Pauksens","year":"2017","journal-title":"ID Week"},{"issue":"6","key":"10.1016\/j.vaccine.2018.07.005_b0185","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","article-title":"Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults","volume":"14","author":"Schwarz","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.07.005_b0190","article-title":"Quality of life impact of a recombinant zoster vaccine in adults \u226550 years of age","author":"Curran","year":"2018","journal-title":"J. Gerontol A Biol Sci Med Sci"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.07.005_b0195","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.2105\/AJPH.2008.151332","article-title":"Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study","volume":"99","author":"Nelson","year":"2009","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2018.07.005_b0200","unstructured":"Prosser L, Economic evaluation of vaccination for prevention of herpes zoster and related complications. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2017-10\/zoster-03-prosser.pdf [accessed 2018 15 May]."},{"issue":"9","key":"10.1016\/j.vaccine.2018.07.005_b0205","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4065\/84.9.787","article-title":"Health care utilization and cost burden of herpes zoster in a community population","volume":"84","author":"Yawn","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2018.07.005_b0210","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.005_b0215","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/jama.2010.1983","article-title":"Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease","volume":"305","author":"Tseng","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.005_b0220","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4065\/mcp.2010.0618","article-title":"Herpes zoster recurrences more frequent than previously reported","volume":"86","author":"Yawn","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.vaccine.2018.07.005_b0225","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/infdis\/jis334","article-title":"Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population","volume":"206","author":"Tseng","year":"2012","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.07.005_b0230","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3111\/13696998.2011.607482","article-title":"Work and productivity loss related to herpes zoster","volume":"14","author":"Singhal","year":"2011","journal-title":"J Med Econ."},{"key":"10.1016\/j.vaccine.2018.07.005_b0235","unstructured":"United States Bureau of Labor Statistics. Median usual weekly earnings of full-time wage and salary workers by age, race, Hispanic or Latino ethnicity, and sex, first quarter 2015 averages, not seasonally adjusted; 2016. Available from: http:\/\/www.bls.gov\/news.release\/wkyeng.t03.htm [accessed 2017 24 August]."},{"key":"10.1016\/j.vaccine.2018.07.005_b0240","unstructured":"United States Bureau of Labor Statistics. Employment status of the civilian noninstitutional population by age, sex, and race; 2016. Available from: http:\/\/www.bls.gov\/cps\/cpsaat03.htm [accessed 2017 24 August]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18309356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:26:46Z","timestamp":1759400806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18309356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":48,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X18309356"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}